Streetbeat News

Analyst Ratings

EEX

Rosenblatt analyst Barton Crockett has maintained a 'Buy' rating on Emerald Holding (NYSE:EEX) and raised the price target from $7.2 to $8.4.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:44 pm

RNG

Needham analyst Ryan Koontz has reiterated a 'Buy' rating on RingCentral (NYSE:RNG) and maintained a price target of $46.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:43 pm

ICHR

Needham analyst Quinn Bolton maintains a Buy rating on Ichor Holdings (NASDAQ:ICHR) but lowers the price target from $40 to $34.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:42 pm

RCKT

Needham analyst Gil Blum has reiterated a 'Buy' rating on Rocket Pharmaceuticals (NASDAQ:RCKT) and maintained a price target of $53.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:42 pm

AAPL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo discusses trading strategies for SPY, QQQ, AAPL, MSFT, NVDA, META, and TSLA. The memo provides price levels for each asset, based on a proprietary formula that takes into account price, volume, and options flow. The memo suggests potential price movements for each asset, both in bullish and bearish scenarios.

Portfolio Pulse from RIPS

November 07, 2023 | 3:40 pm

CRSP

Needham analyst Gil Blum maintains a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) but lowers the price target from $88 to $85.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:40 pm

GFL

TD Cowen analyst James Schumm has initiated coverage on GFL Environmental (NYSE:GFL) with an Outperform rating and a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:37 pm

GRNT

B of A Securities analyst John Abbott has initiated coverage on Granite Ridge Resources (NYSE:GRNT) with a Buy rating and a price target of $9.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:36 pm

AUPH

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) presented five studies at the annual American College of Rheumatology Convergence 2023, reinforcing the safety and effectiveness of LUPKYNIS® (voclosporin) for the treatment of adult patients with active lupus nephritis. The studies showed that initial therapy with LUPKYNIS® plus standard of care improved safety and demonstrated earlier reductions in proteinuria compared to a conventional regimen. The data also showed an improved safety profile over the first six months of treatment with LUPKYNIS® in combination with low-dose glucocorticoids and lower-dose MMF without compromising efficacy.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:35 pm

HD

RBC Capital analyst Steven Shemesh has initiated coverage on Home Depot (NYSE:HD) with a Sector Perform rating and a price target of $303.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 3:34 pm